DAYQUIL COLD & FLU LIQUID OTC
Generic Name and Formulations:
Acetaminophen 325mg, dextromethorphan HBr 10mg, phenylephrine HCl 5mg; per 15mL; liq; contains sodium 71mg/15mL.
Procter & Gamble Pharmaceuticals
Indications for DAYQUIL COLD & FLU LIQUID:
Nasal congestion, cough, sore throat, fever, headache, minor aches and pains.
Adults and Children:
<6yrs: not recommended. 6–11yrs: 15mL. ≥12yrs: 30mL. All: repeat every 4 hours; max 5 doses/24 hours (children) or 6 doses/24 hours (adults).
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. GI or GU obstruction. Thyroid disease. Diabetes. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers. Liquid: sodium-restricted diet.
Analgesic + antitussive + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day. β-blockers may increase the pressor effects of sympathomimetics. Antagonizes antihypertensives.
Nervousness, dizziness, insomnia, hepatotoxicity (overdosage).
LiquiCaps—12, 20, 40, 60; Liq—6oz
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC